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In spite of antithrombotic therapy, the thromboembolic risk after aortic valve replace-ment appears to be high for the first 3 months after surgical intervention (3.6%),especially during the first 10 postoperative days.1
We have previously shown that 100 mg of aspirin, a dose that is effective for early
antithrombotic treatment after coronary artery bypass grafting (CABG), did not sufficiently
inhibit platelet function in patients subjected to CABG, indicating a remarkable resistance
against the antiplatelet effect of aspirin in the early postoperative period.2
The present work determined platelet function early after aortic valve replacement and
examined whether the antiplatelet effect of aspirin, based on the inhibition of platelet
thromboxane production, is impaired in the early postoperative period.
Methods
Subjects and drug administration. This study was conducted in agreement with the
Declaration of Helsinki and was approved by the institutional ethics committee. Fifteen
consecutive patients were included who underwent an elective aortic valve replacement with
bileaflet mechanical prostheses (St Jude Medical). Informed consent was obtained from each
participant. Drugs affecting hemostasis (including aspirin) had been terminated at least 7 days
before surgical intervention. Antithrombotic therapy was initiated the first day after surgical
intervention with heparin (3  10,000 IU administered subcutaneously). At day 3 after
surgical intervention, anticoagulation with a vitamin K antagonist (phenprocoumon) was
initiated, and heparin was terminated when a target international normalized ratio (INR) of
2.5 had been reached.
Measurement of platelet function. One day before and at days 1, 5, and 10 after
surgical intervention arachidonic acid (1 mmol/L)–induced aggregation and thromboxane
formation were determined in venous blood samples.2 Because thromboxane formation by
platelet cyclooxygenase is the pharmacologic target of aspirin, the sensitivity of platelets to
aspirin in vitro was determined by means of addition of aspirin (100 mol/L).
Statistics. Data are presented as mean values the standard error of the mean. Statistical
analyses were performed with 2-way analysis of variance for repeated measurements with the
Tukey post-hoc test.
Results
Platelet counts decreased from 252  20/nL (before surgical intervention) to 143  14/nL
(day 1 after CABG, P  .05) and increased to 239  22/nL at day 5 and 325  31/nL at day
10.
Before surgical intervention, arachidonic acid (1 mmol/L) caused a considerable platelet
release of thromboxane (Figure 1). This was significantly reduced at day 1 after valve
replacement, as shown by a decay of thromboxane to 39%  12% of the control value (P 
.05). Thereafter, platelet function recovered (117%  25% at day 5), and thromboxane
formation was more than doubled at day 10 (249%  55%, P  .05) compared with control
values seen before surgical intervention.
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This activation of thromboxane formation was also reflected in
the platelet aggregation (Figure 2). At days 1, 5, and 10 after
surgical intervention, platelet aggregation was 38%  11%,
95% 15%, and 145%  14%, respectively, of the control value
before surgical intervention.
Although the antiplatelet effect of aspirin was attenuated com-
pared with the control value before surgical intervention, aspirin in
vitro (100 mol/L) inhibited platelet function significantly at days
5 and 10.
Discussion
The major finding of this study is that platelet thromboxane for-
mation and aggregation are increased early after aortic valve
replacement (with mechanical bileaflet prostheses), indicating re-
markable platelet activation. This is in accordance with the in-
creased risk of thrombembolism during the first weeks after valve
replacement.1 Our study is also, to the best of our knowledge, the
first to show a significantly increased thromboxane biosynthesis.
The observed platelet hyperreactivity after valve replacement
might have resulted from an increased regeneration of young
hyperreactive platelets because of transient depletion caused by
extracorporeal circulation. Shear stress–induced activation by the
valve prosthesis might also have contributed. Indeed, the shear
stress created by prosthetic heart valves has earlier been shown to
induce platelet aggregation.3
American College of Chest Physicians Guidelines recommend
vitamin K antagonists and heparin for patients with mechanical
valves in the aortic position until the INR is stable and within the
therapeutic range for 2 consecutive days. Additional therapy with
aspirin is presently recommended only for patients who have
systemic embolism despite a therapeutic INR and in patients with
additional risk factors.4 Nevertheless, aspirin appeared to prevent
thromboembolism caused by mechanical bileaflet prostheses (eg,
St Jude Medical) in the aortic position almost as efficiently as full
anticoagulation, with a lower rate of bleeding.5
In conclusion, the increased thromboxane formation after valve
replacement makes aspirin conceivable as an adjunct to vitamin K
antagonists early after surgical intervention, especially in patients
at high risk for thrombembolic events.
References
1. Heras M, Chesebro JH, Fuster V, Penny WJ, Grill DE, Bailey KR, et al.
High risk of thrombembolism early after bioprosthetic cardiac valve
replacement. J Am Coll Cardiol. 1995;25:1111-9.
2. Zimmermann N, Wenk A, Kienzle P, Weber AA, Gams E, Schrör K,
et al. Functional and biochemical evaluation of platelet aspirin resis-
tance after coronary artery bypass surgery. Circulation. 2003;108:
542-7.
3. Scharf RE, Giers G. Molecular mechanisms and indicators of throm-
bogenesis after heart valve replacement. Z Kardiol. 1998;87(suppl 4):
7-19.
4. Salem DN, Stein PD, Al-Ahmad A, Bussey HI, Horstkotte D, Miller N,
et al. Antithrombotic therapy in valvular heart disease—native and
prosthetic. Chest. 2004;126(suppl):457S-82S.
5. von Schacky C. Inhibition of thrombocyte aggregation after heart valve
replacement. Z Kardiol. 1998;87(suppl 4):46-55.
Figure 1. Arachidonic acid (1 mmol/l)–induced platelet thrombox-
ane formation in platelet-rich plasma of patients (n  15) before
(control) and at the indicated times after aortic valve replace-
ment. The measurements have been performed without (open
bars) or with (filled bars) addition of aspirin in vitro (100 mol/L).
*Significant differences (P < .05) versus corresponding measure-
ment without aspirin; #significant differences (P < .05) versus
control values before surgical intervention. ASS, aspirin.
Figure 2. Arachidonic acid (1 mmol/l)–induced platelet aggrega-
tion in platelet-rich plasma of patients (n  15) before (control)
and at the indicated times after aortic valve replacement. The
measurements have been performed without (open bars) or with
(filled bars) addition of aspirin in vitro (100 mol/L). *Significant
differences (P < .05) versus corresponding measurement without
aspirin; #significant differences (P < .05) versus control values
before surgical intervention. ASS, aspirin.
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